ARROWHEAD PHARMACEUTICALS, INC. (19)
Browse by Contract Category
Contracts
-
Open Market Sale Agreement, dated as of December 2, 2022, by and between Arrowhead Pharmaceuticals, Inc. and Jefferies, LLC
(Filed With SEC on December 8, 2022)
-
First Amendment to Exclusive License and Co-Funding Agreement by and between Arrowhead Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. dated March 15, 2022
(Filed With SEC on May 10, 2022)
-
Collaboration and License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics Ireland DAC, dated June 18, 2021
(Filed With SEC on August 5, 2021)
-
Form of RSU Agreement (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan)
(Filed With SEC on August 5, 2021)
-
Amendment No. 3 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated January 11, 2019
(Filed With SEC on November 23, 2020)
-
Underwriting Agreement, dated as of December 3, 2019, among Arrowhead Pharmaceuticals, Inc. and Goldman Sachs & Co. LLC, Jefferies, LLC, and Piper Jaffray & Co., as...
(Filed With SEC on December 6, 2019)
-
Form of Stock Option Agreement (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan)
(Filed With SEC on August 5, 2021)
-
Form of Performance RSU Agreement (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan)
(Filed With SEC on August 5, 2021)
-
Amendment No. 5 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated May 14, 2020
(Filed With SEC on November 23, 2020)
-
Amendment No. 4 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated September 19, 2019
(Filed With SEC on November 23, 2020)
-
Amendment No. 2 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated January 10, 2019
(Filed With SEC on November 23, 2020)
-
Amendment No. 1 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated October 22, 2018
(Filed With SEC on November 23, 2020)
-
Open Market Sale Agreement, dated as of August 5, 2020, by and between Arrowhead Pharmaceuticals, Inc. and Jefferies LLC
(Filed With SEC on August 5, 2020)
-
Sublease agreement by and between Halozyme, Inc. and Arrowhead Pharmaceuticals Inc. dated March 3, 2020
(Filed With SEC on May 7, 2020)
-
Amendment No. 1 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated December 18, 2018
(Filed With SEC on November 25, 2019)
-
Amendment No. 1 to Research Collaboration and Option Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated November 14, 2019
(Filed With SEC on November 25, 2019)
-
Amendment No. 2 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated February
(Filed With SEC on November 25, 2019)
-
Description of Registrants Securities
(Filed With SEC on November 25, 2019)
-
Lease Agreement between Arrowhead Pharmaceuticals, Inc. and 177 Colorado Owner LLC, dated April 17, 2019
(Filed With SEC on August 5, 2019)